ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Single-cell and spatial transcriptome-based metabolism-immunity interaction network and therapeutic target discovery of matrine in cervical cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although its exact mechanism is yet unknown, cervical cancer is a very common malignant tumor in the world. Its growth is strongly linked to metabolic imbalance and tumor microenvironment heterogeneity. Further research is necessary to determine if the natural substance matrine's multi-targeted anti-tumor capability is due to metabolic reprogramming or immune microenvironment regulation. The purpose of this study is to provide a new research direction and theoretical foundation for the treatment of cervical cancer by thoroughly examining the molecular mechanism of the disease and assessing the potential of matrine intervention through the integration of TCGA database analysis, single-cell sequencing, and spatial transcriptome technology. To extensively examine the differential gene expression characteristics, immune microenvironment heterogeneity, and metabolic pathway regulation network of cervical cancer, we combined TCGA database analysis, single-cell sequencing, and spatial transcriptome technologies. The immune and stromal scores of tumor tissues were evaluated using the CIBERSORT and ESTIMATE algorithms, and the metabolic-immune interactions between immune and malignant cells were discovered by single-cell sequencing. Furthermore, matrine's mode of action was examined using bioinformatics, and its possible therapeutic targets were preliminarily indicated using in vitro tests and molecular docking. Using TCGA database analysis, 758 differential genes were screened for this investigation. Of these, 453 overlapped with cervical cancer targets in the CTD database. Additionally, 20 hub genes were found, primarily involved in DNA damage repair, chromosome segregation, and cell cycle regulation. Enrichment study revealed that cervical cancer has markedly activated metabolic pathways, including the calcium signaling pathway, the neuroactive ligand-receptor interaction, and glycolysis/tricarboxylic acid cycle (TCA). While CD8 + T cell function may be inhibited, immuno-microenvironmental examination showed a considerable increase in the infiltration of neutrophils, NK cells, and macrophages in tumor tissues. Furthermore, by targeting genes that control calcium signaling, cAMP, and inflammation-related pathways, including BCHE, HTR2B, PLA2G2C, PTGER3, and TACR1, this intervention may have the potential to suppress tumor malignancy. By combining multilevel data, this study uncovers the fundamental mechanism of the metabolism-immunity interaction in cervical cancer and suggests a novel approach for hormone-targeted therapy. Our preliminary results indicate that this treatment can upregulate or downregulate certain genes associated with malignant tumors at the mRNA level.
Indexed as
Identifiers
41283998What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.